Immuron Limited (ASX:IMC) has disclosed that shareholders passed two of five resolutions at the company's 2026 Annual General Meeting held on 18 November 2026, with the adoption of the 2026 Remuneration Report attracting more than 25% of votes against, constituting a "first strike" under section 250U of the Corporations Act 2001.
Key Points
- Resolutions 1 and 2 were passed at the 2026 Annual General Meeting on 18 November 2026
- Resolutions 3, 4 and 5 were not carried
- More than 25% of votes cast on Resolution 1 were against adoption of the 2026 Remuneration Report
- The vote against Resolution 1 constitutes a "first strike" under section 250U of the Corporations Act 2001
- All resolutions were determined by way of a poll
2026 Annual General Meeting Voting Outcomes
Immuron Limited, an Australian biopharmaceutical company listed on both the ASX and NASDAQ, held its 2026 Annual General Meeting on 18 November 2026. According to the company's filing, shareholders voted on five resolutions in total. Resolutions 1 and 2 were passed, while Resolutions 3, 4 and 5 were not carried. The company disclosed the results in accordance with ASX Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act 2001. All resolutions put to the meeting were determined by way of a poll, with full proxy details set out in the attached proxy summary accompanying the filing.
First Strike Recorded Against 2026 Remuneration Report
In accordance with ASX Listing Rule 3.13.2(f), Immuron disclosed that more than 25% of the votes cast on Resolution 1, which concerned the adoption of the 2026 Remuneration Report, were cast against the resolution. Under section 250U of the Corporations Act 2001, this outcome constitutes a "first strike" against the company's remuneration report. The filing states the company made this disclosure in compliance with the relevant ASX Listing Rule requirement. No further detail on the specific vote counts or percentages was provided beyond the threshold disclosure.
Filing Authorisation and Company Details
The company update was authorised for release by the Company Secretary, according to the filing. Immuron Limited is described in the filing as an Australian biopharmaceutical company focused on developing and commercialising orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. The company holds dual listings on the ASX under the ticker IMC and on the NASDAQ under the ticker IMRN. The filing was lodged simultaneously as an ASX and NASDAQ announcement dated 18 November 2026.



Please wait processing your request...